Case File
efta-01789412DOJ Data Set 10OtherEFTA01789412
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01789412
Pages
3
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Melanie Spinella
Sent:
Thursday, Januarylil ligill
m
To:
jeffrey E.
Subject:
RE: FW: MRA/Epstein Letter and Invoice
thanks
From: jeffrey E. [mailto:[email protected][
Sent: Thursday, January 28, 2016 12:33 PM
To: Melanie Spinella
Subject: Re: FW: MRA/Epstein Letter and Invoice
yes it gets paid end of jan, with pleasure
On Thu, Jan 28, 2016 at 12:28 PM, Melanie Spinella IMINI
IMIIMM:.>
wrote:
Not sure if you ever received the original.
From: Lauren Leiman
[mailto
Sent: Thursday, January 28, 2016 12:06 PM
To: Melanie Spinella
Subject: MRA/Epstein Letter and Invoice
Attached and below is invoice and letter from MRA Acting CEO Margaret Anderson to Jeffrey Epstein for his $225,000
2015 MRA gift.
Thank you!
-L
January 28, 2016
Attn: Jeffrey Epstein
EFTA_R1_00115786
EFTA01789412
[email protected] <mailto:[email protected]>
Jeffrey Epstein VI Foundation
Dear Mr. Epstein:
We are so grateful for your continued support of our work at the Melanoma Research Alliance (MRA). We were
delighted to receive your commitment to MRA's biennial benefit dinner at Sotheby's to support MRA's research
portfolio.
More than 200 supporters joined us in celebrating the progress taking place in the field of melanoma research during
our benefit dinner last month. It truly was a wonderful night, as we honored the scientists and doctors who are
dedicated to defeating this disease, and also raised $5.8 million. As you know, 100% of all funds raised go directly to
support MRA's research program.
Please allow this letter to serve as confirmation of your pledge for $225,000 for a Young Investigator Award. The Young
Investigator Award program aims to attract early career scientists with novel ideas into melanoma research, thereby
recruiting and supporting the next generation of melanoma scientists.
Since we began our work, we have seen dramatic progress in the field, with 11 new therapies coming to market for
patients with melanoma — including three in the last month! MRA has been at the forefront of some of the most
promising research, providing critical funding to elevate the pace of discovery. The impact is being felt throughout the
field of oncology.
Enclosed please find an invoice for your commitment. Please contact Logan Kastner, Director of Development and
Marketing, at (202) 336-8944 <tel:%28202%29%20336-8944> or [email protected]
<mailto:[email protected]> , with any questions.
At the Melanoma Research Alliance, we are committed to funding the best research and brightest minds throughout the
world. With your support, we will continue to change the field for all those impacted by melanoma.
With sincere appreciation,
2
EFTA_R1_00115787
EFTA01789413
Margaret Anderson
Acting President & CEO
This email and any files transmitted with it are confidential and intended solely for the person or entity to whom they
are addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or
other use of, or taking of any action in reliance upon this information by persons or entities other than the intended
recipient is prohibited. If you have received this email in error please contact the sender and delete the material from
any computer. Apollo Global Management, LLC
please note
The information contained in this communication is confidential, may be attorney-client privileged, may constitute
inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use,
disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have
received this communication in error, please notify us immediately by return e-mail or by e-mail to
[email protected] <mailto:[email protected]> , and destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
This email and any files transmitted with it are confidential and intended solely for the person or entity to whom they
are addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or
other use of, or taking of any action in reliance upon this information by persons or entities other than the intended
recipient is prohibited. If you have received this email in error please contact the sender and delete the material from
any computer. Apollo Global Management, LLC
3
EFTA_R1_00115788
EFTA01789414
Technical Artifacts (4)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.